Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06068426
Other study ID # 2021-0499
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 13, 2021
Est. completion date August 1, 2024

Study information

Verified date September 2023
Source Children's Hospital Medical Center, Cincinnati
Contact Tyler Thompson, BS
Phone 513-517-1055
Email tyler.thompson@cchmc.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main reason for this research study is to find out more about acute recurrent pancreatitis and chronic pancreatitis in children. There are few studies on childhood pancreatitis, so diagnosis and treatment are based on adult studies. This limits our understanding and treatment of these disorders in children. Endoscopic ultrasound (EUS) is a tool used to assess and diagnose pancreatic disease. We can use ultrasound with shear wave elastography (SWE) to measure fibrosis (scarring) of the pancreas. We can use SWE on both EUS and transabdominal ultrasound (TUS) systems. Both TUS and EUS SWE have been studied for diagnosis of chronic pancreatitis in adult patients, however they have not been studied in children. We plan to use EUS SWE and TUS SWE information in this study to help us understand pancreatitis in children. Children with pancreatitis and children without pancreatitis (controls) will be invited to participate in this study.


Description:

The aims of the proposed study are as follows: Aim 1: Characterize endoscopic ultrasound (EUS) findings of pediatric acute recurrent pancreatitis (ARP) and chronic pancreatitis (CP). Adult criteria for EUS diagnosis of CP exist, but no such criteria exist for children. As such, the applicability of current diagnostic criteria to pediatric patients is unknown. 1.1: Catalogue grayscale EUS findings of ARP and CP in a pediatric cohort and compare to healthy controls. Hypothesis: EUS findings of ARP and CP in pediatric patients will differ from those of adult ARP and CP and will be characteristically different from healthy controls. Exp1: We will catalogue grayscale EUS findings in 40 pediatric patients with known history of ARP or CP undergoing clinically indicated EUS and will compare those with findings in 20 patients without a history of pancreatitis who are undergoing EUS for other indications. 1.2: Benchmark grayscale EUS against other imaging modalities for diagnosis of CP, particularly early CP, in children. Hypothesis: Grayscale EUS findings will be more sensitive than other imaging modalities in all stages of CP. Exp2: We will test associations, in blinded fashion, of grayscale EUS findings catalogued under S.A1.1 in enrolled children with findings on alternative pancreas imaging modalities performed for clinical indications. Specifically, we will correlate to endoscopic retrograde cholangiopancreatography (ERCP), magnetic resonance cholangiopancreatography (MRCP) and computed tomography (CT) performed for clinical indications within +/- 3 months of the EUS. Aim 2: Define the diagnostic performance of ultrasound elastography for CP and pancreatic stiffness as a measure of fibrosis in pediatric patients. 2.1: Define the diagnostic performance of EUS and TUS elastography for pediatric CP. Hypothesis: EUS and TUS elastography will have high specificity for CP with increased stiffness in patients compared to controls. Exp 1: Patients enrolled under Aim 1 will undergo shear wave elastography (SWE) measurement of the pancreas during EUS. These same patients will undergo research TUS with SWE of the pancreas. SWE results by both EUS and TUS will be evaluated for diagnostic performance for CP. 2.2: Define agreement between EUS and TUS measurement of pancreatic parenchymal stiffness in pediatric patients. Hypothesis: EUS and TUS measures of pancreatic parenchymal stiffness will agree with minimal bias. Exp2: EUS and TUS SWE data obtained under S.A2.1 will be evaluated for agreement and divergent cases will be investigated to define causes. 2.3: Define the diagnostic performance of elastography for pancreatic fibrosis. Hypothesis: SWE is a sensitive indicator of pancreatic fibrosis as identified by histology. Exp3: Patients undergoing clinically indicated total pancreatectomy and islet auto transplant (TPIAT) or other pancreatic surgical resection at our institution (approximately 20 per year) will be approached to undergo pre-operative TUS SWE. These SWE measurements, along with EUS SWE measurements obtained preoperatively, will be compared to binary and semi-quantitative assessments of pancreatic parenchymal fibrosis by histology.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date August 1, 2024
Est. primary completion date December 31, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 0 Years to 21 Years
Eligibility Pancreatitis Cohort: Inclusion criteria: - Confirmed diagnosis of ARP or CP by INSPPIRE criteria - = 21 years of age, male and female - Children undergoing EUS for clinical care - For Aim 2.3 only: Children undergoing TPIAT or other pancreatic resection Exclusion criteria: - Children <15 kg who cannot accommodate the size of endoscope - Children with acute pancreatitis (AP) <6 weeks prior to EUS Control Cohort: Inclusion criteria: - Children without a history of pancreatic disease undergoing EUS for other clinical indications - = 21 years of age, male and female Exclusion criteria: - Children <15 kg who cannot accommodate the size of endoscope - Children with AP, ARP or CP

Study Design


Intervention

Diagnostic Test:
Transabdominal ultrasound Shear wave elastography
TUS SWE will be performed using a Canon Aplio i800 ultrasound system and a curved 1-6 MHz transducer. 2D SWE will be performed with measurement of shear wave speed in the head, body and tail of the pancreas.

Locations

Country Name City State
United States Cincinnati Children's Hospital Medical Center Cincinnati Ohio

Sponsors (1)

Lead Sponsor Collaborator
David Vitale MD

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary EUS Pancreatic findings- Rosemont Criteria - Features
Hyperechoic foci with shadowing (Major A)
Lobularity with honeycombing (Major B)
Lobularity without honeycombing (Minor)
Hyperechoic foci without shadowing (Minor)
Cysts (Minor)
Stranding (Minor)
Main pancreatic duct calculi (Major A)
Irregular main pancreatic duct contour (Minor)
Dilated side branches (Minor)
Main pancreatic duct dilation (Minor)
Hyperechoic main pancreatic duct margin (Minor)
6 months (3 months prior to endoscopic ultrasound through 3 months post-endoscopic ultrasound)
Secondary Calculated BMI Capturing weight(kg) and height(cm) to calculate 6 months (3 months prior to endoscopic ultrasound through 3 months post-endoscopic ultrasound)
Secondary Acute recurrent pancreatitis Y/N 6 months (3 months prior to endoscopic ultrasound through 3 months post-endoscopic ultrasound)
Secondary CP findings Ductal calculi, dilated side branches, parenchymal calcifications found in any imaging (abdominal ultrasound (abd US), magnetic resonance imaging/magnetic resonance cholangiopancreatography (MRI/MRCP), computerized tomography (CT), endoscopic retrograde cholangiopancreatography (ERCP), endoscopic US (EUS).
Ductal obstruction or stricture/dilatation/irregularities that are persistent (for >2 months) on any imaging.
Surgical or pancreatic biopsy specimen demonstrating histopathologic features compatible with CP (acinar atrophy, fibrosis, protein plugs, infiltration with lymphocytes, plasma cells, macrophages).
6 months (3 months prior to endoscopic ultrasound through 3 months post-endoscopic ultrasound)
Secondary Exocrine pancreatic insufficiency Y/N 6 months (3 months prior to endoscopic ultrasound through 3 months post-endoscopic ultrasound)
Secondary Diabetes medication Y/N 6 months (3 months prior to endoscopic ultrasound through 3 months post-endoscopic ultrasound)
Secondary EUS SWE Head (Vs m/s) median, IQR, # measurements
Genu (Vs m/s) median, IQR, # measurements
Body (Vs m/s) median, IQR, # measurements
Tail (Vs m/s), median, IQR, # measurements
6 months (3 months prior to endoscopic ultrasound through 3 months post-endoscopic ultrasound)
Secondary TUS SWE Head (Vs m/s) median, IQR, # measurements
Body (Vs m/s) median, IQR, # measurements
Tail (Vs m/s), median, IQR, # measurements
6 months (3 months prior to endoscopic ultrasound through 3 months post-endoscopic ultrasound)
Secondary MRI Findings- Atrophy (Y/N) 6 months (3 months prior to endoscopic ultrasound through 3 months post-endoscopic ultrasound)
Secondary CT Findings- Atrophy (Y/N) 6 months (3 months prior to endoscopic ultrasound through 3 months post-endoscopic ultrasound)
Secondary CT Findings- Calcifications parenchymal/duct/both/no 6 months (3 months prior to endoscopic ultrasound through 3 months post-endoscopic ultrasound)
Secondary CT Findings- Duct Dilation (Y/N) 6 months (3 months prior to endoscopic ultrasound through 3 months post-endoscopic ultrasound)
Secondary CT Findings- Enhancement hypoenhancing/normal/hyperenhancing/heterogeneous/NA 6 months (3 months prior to endoscopic ultrasound through 3 months post-endoscopic ultrasound)
Secondary CT Findings- Acute Pancreatitis Y/N 6 months (3 months prior to endoscopic ultrasound through 3 months post-endoscopic ultrasound)
Secondary ERCP Cambridge findings - Cambridge Criteria
1 (Normal)
2 (Equivocal)
3 (Mild)
4 (Moderate)
5 (Marked)
6 months (3 months prior to endoscopic ultrasound through 3 months post-endoscopic ultrasound)
Secondary Specimen Histology- Fibrosis Score Four-stage scoring system: 0 = normal pancreas parenchyma, no fibrotic changes; 1 = mild fibrosis with thickening of periductal fibrous tissue; 2 = moderate fibrosis with marked sclerosis of interlobular septa, no evidence of architectural changes, and 3 = severe fibrosis with detection of architectural destruction. 6 months (3 months prior to endoscopic ultrasound through 3 months post-endoscopic ultrasound)
Secondary EUS Pancreatic findings- Pancreatic duct size (mm) (include all measured) Head of pancreas ___
Genu ____
Body ____
Tail ____
6 months (3 months prior to endoscopic ultrasound through 3 months post-endoscopic ultrasound)
Secondary EUS Pancreatic findings- Diffuse hyperechogenicity Y/N 6 months (3 months prior to endoscopic ultrasound through 3 months post-endoscopic ultrasound)
Secondary MRI Findings- T1 SIR measurements Pancreas signal 1 _____
Pancreas signal 2 _____
Pancreas signal 3 _____
Spleen signal 1 _____
Spleen signal 2 _____
Spleen signal 3 _____
Muscle signal 1 _____
Muscle signal 2 _____
Muscle signal 3 _____
6 months (3 months prior to endoscopic ultrasound through 3 months post-endoscopic ultrasound)
Secondary MRI Findings- Calculated T1 SIR spleen (average of 3 pancreas measures)/(average of 3 spleen measures) 6 months (3 months prior to endoscopic ultrasound through 3 months post-endoscopic ultrasound)
Secondary MRI Findings- Calculated T1 SIR muscle (average of 3 pancreas measures)/(average of 3 muscle measures) 6 months (3 months prior to endoscopic ultrasound through 3 months post-endoscopic ultrasound)
Secondary MRI Findings- T1 MOLLI MOLLI 1 _____
MOLLI 2 _____
MOLLI 3 _____
6 months (3 months prior to endoscopic ultrasound through 3 months post-endoscopic ultrasound)
Secondary MRI Findings- Enhancement hypoenhancing/normal/hyperenhancing/heterogeneous/NA 6 months (3 months prior to endoscopic ultrasound through 3 months post-endoscopic ultrasound)
Secondary MRI Findings- Cambridge Criteria 1 (Normal)
2 (Equivocal)
3 (Mild)
4 (Moderate)
5 (Marked)
6 months (3 months prior to endoscopic ultrasound through 3 months post-endoscopic ultrasound)
Secondary MRI Findings- Pancreas PDFF (%) PDFF 1 ____
PDFF 2 ____
PDFF 3 ____
6 months (3 months prior to endoscopic ultrasound through 3 months post-endoscopic ultrasound)
Secondary MRI Findings- Acute Pancreatitis Y/N 6 months (3 months prior to endoscopic ultrasound through 3 months post-endoscopic ultrasound)
See also
  Status Clinical Trial Phase
Completed NCT03112759 - Assessing the Utility of Cognitive Behavioral Therapy for Pain Control in Patients With Chronic Pancreatitis N/A
Enrolling by invitation NCT05410795 - Establishment and Verification of Pancreatic Volume Formula Based on Imaging
Active, not recruiting NCT02965898 - The Effect of Vitamin D Substitution on the Development of Chronic Pancreatitis N/A
Completed NCT01452217 - Non-invasive MRI to Quantify the Effect of Secretin on Pancreatic Blood Flow and Perfusion in Healthy Volunteers Phase 1
Completed NCT02868047 - Establishing Standards for Normal Pancreatic EUS N/A
Completed NCT00685087 - A Prospective Study of Natural History of Pancreatitis N/A
Completed NCT04949828 - Effect of CREON on Exocrine Pancreatic Insufficiency (EPI) Symptoms
Active, not recruiting NCT05042284 - Effect of Non-enteric Coated Enzymes Substitution on Pain in Patients With Chronic Pancreatitis N/A
Active, not recruiting NCT05764629 - An Observational Study on Post-chronic Pancreatitis Diabetes Mellitus
Completed NCT03850977 - Is There an Association Between Chronic Pancreatitis and Pulmonary Function
Recruiting NCT05692596 - The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
Recruiting NCT06015945 - Role of Home-based Transcutaneous Electrical Acustimulation for Treatment of Pain in Patients With Chronic Pancreatitis N/A
Completed NCT04619511 - Risk Factors for Post-ESWL and Post-ERCP Pancreatitis
Completed NCT03283566 - Hydroxychloroquine and Metabolic Outcomes in Patients Undergoing TPAIT Phase 2
Recruiting NCT03434392 - QST Study: Predicting Treatment Response in Chronic Pancreatitis Using Quantitative Sensory Testing N/A
Completed NCT01430234 - Enzyme Suppletion in Exocrine Pancreatic Dysfunction Phase 4
Completed NCT01318369 - Efficacy Study of Δ9-THC to Treat Chronic Abdominal Pain Phase 2
Terminated NCT01442454 - Endoscopic Ultrasound (EUS) Features of Chronic Pancreatitis N/A
Completed NCT00755573 - Pain and Chronic Pancreatitis - Clinical End Experimental Studies Phase 2/Phase 3
Completed NCT00414908 - A Study to Investigate the Effect of Delayed Release Pancrelipase on Maldigestion in Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis and Pancreatectomy Phase 3